Paysign Q2 Revenue Soars 48% to $28.3M, Raises Full-Year Outlook
PAYS has more than doubled off its 52-week low of $3.08.
Summary
Paysign delivered a blowout Q2 with revenue jumping 48% to $28.3M, driven by an 89% surge in pharma patient affordability revenue and 21% growth in plasma. Net income exploded 387% to $6.76M, or $0.11 per share, while adjusted EBITDA more than doubled to $9.61M. Margins expanded sharply — gross margin hit 63.3% and operating margin reached 24.8% — reflecting operating leverage as the higher-margin pharma business scales. Management raised the full-year outlook, signaling confidence in sustained momentum. This follows a strong Q1 that saw 51% revenue growth and a doubling of net income, confirming an accelerating trend. The stock is trading near its 52-week high, and these results justify the premium. The raised guidance and margin expansion are the key takeaways — the pharma pipeline is delivering, and plasma utilization is improving despite center closures. Watch for analyst revisions and potential upward repricing as the market digests the magnitude of the beat and raise.
At the time of this announcement, PAYS was trading at $9.68 on NASDAQ in the Finance sector, with a market capitalization of approximately $536.1M. The 52-week trading range was $3.08 to $9.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.